Financial Trends -- 7/10
Revenue re-accelerated to +11.8% at $11.0B, but ~60% of headline growth was M&A-driven
(LifeLabs, outreach acquisitions). Organic revenue growth of 5.3% was well above industry norms.
Adj EPS grew +10.3% to $9.85 after two years of post-COVID compression. FCF surged +49.5% to
$1.36B, though ~$150M came from one-time items. Margins remain compressed vs the COVID peak --
adj op margin of 15.9% vs 23.8% in 2021 -- with LifeLabs dilutive near-term.
Weight: 25%
FY25 Revenue
$11.0B
+11.8% YoY | Organic 5.3%
FY25 Adj EPS
$9.85
+10.3% YoY | Recovery from trough
FY25 Adj Op Margin
15.9%
+30 bps YoY | Still well below COVID peak
FY25 Free Cash Flow
$1,359M
+49.5% YoY | Some one-time benefit
Annual Financial Summary ($M, FY ends December)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net Revenue | $9,437M | $10,788M | $9,883M | $9,252M | $9,872M | $11,035M |
| Rev YoY | — | +14.3% | -8.4% | -6.4% | +6.7% | +11.8% |
| Organic Rev Growth | — | — | — | — | ~3.0% | 5.3% |
| Test Requisitions (M) | 187M | 218M | 208M | 206M | 217M | 244M |
| Req YoY | — | +16.6% | -4.6% | -1.0% | +5.3% | +12.4% |
| Rev/Req YoY | +16.2% | -1.6% | -4.5% | -5.9% | +1.3% | +0.1% |
| Cost of Services | $5,804M | $6,579M | $6,450M | $6,199M | $6,628M | $7,370M |
| SG&A | $1,550M | $1,727M | $1,874M | $1,642M | $1,770M | $1,967M |
| GAAP Op Income | $1,971M | $2,381M | $1,428M | $1,262M | $1,346M | $1,556M |
| GAAP Op Margin | 20.9% | 22.1% | 14.5% | 13.6% | 13.6% | 14.1% |
| Adj Op Margin | 23.4% | 23.8% | 17.6% | 15.8% | 15.6% | 15.9% |
| Adj Diluted EPS | $11.18 | $14.24 | $9.95 | $8.71 | $8.93 | $9.85 |
| Adj EPS YoY | — | +27.4% | -30.1% | -12.5% | +2.5% | +10.3% |
| Net Income | $1,431M | $1,995M | $946M | $854M | $871M | $992M |
| Cash From Ops | $2,005M | $2,233M | $1,718M | $1,272M | $1,334M | $1,886M |
| CapEx | ($418M) | ($403M) | ($404M) | ($408M) | ($425M) | ($527M) |
| Free Cash Flow | $1,587M | $1,830M | $1,314M | $864M | $909M | $1,359M |
| FCF YoY | — | +15.3% | -28.2% | -34.2% | +5.2% | +49.5% |
| Diluted Shares (M) | 136M | 128M | 118M | 113M | 113M | 113M |
Note: FY2020-2021 revenues include material COVID testing contribution. LifeLabs acquisition
closed mid-2024, contributing to H2 2024 and FY2025 reported growth step-up. FCF = CFO + CapEx
(simple definition). FY2025 CFO includes ~$150M of one-time items per management.
Two consecutive years of revenue growth acceleration:
-6.4% to +6.7% to +11.8%. While headline growth overstates organic momentum (~60%
of 2025 growth was inorganic), organic revenue growth of 5.3% was the strongest in years and
well above the 1-2% historical lab industry norm. Requisitions surged +12.4% to
244M, driven by health plan access
expansion, advanced diagnostics, and consumer-initiated testing.
Margin Trajectory
Margins are directionally improving but remain ~790 bps below
the COVID peak. Adj op margin bottomed at
15.6% in 2024 and expanded +30 bps to
15.9% in 2025. LifeLabs is dilutive to
margins (lower rev/req, below-corp-average profitability) but management expects parity within
2-3 years. The Invigorate program delivers ~3% annual productivity savings.
Quarterly Trends (Q1 2023 through Q4 2025)
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2,331M | $2,338M | $2,295M | $2,288M | $2,366M | $2,397M | $2,488M | $2,621M | $2,652M | $2,761M | $2,816M | $2,806M |
| Rev YoY | — | — | — | — | +1.5% | +2.5% | +8.4% | +14.6% | +12.1% | +15.2% | +13.2% | +7.1% |
| Organic Rev Growth | — | — | — | — | — | — | 4.2% | 5.0% | 2.5% | 5.2% | 6.8% | 6.4% |
| Rev/Req YoY | -7.7% | -4.9% | -7.2% | -3.5% | +0.1% | +1.6% | +3.3% | +0.2% | +0.3% | -0.4% | +0.8% | -0.1% |
| GAAP Op Margin | 13.1% | 14.9% | 14.9% | 11.7% | 12.7% | 14.8% | 13.3% | 13.8% | 13.0% | 15.9% | 13.7% | 13.8% |
| Adj Op Margin | 15.0% | 16.7% | 16.6% | 14.8% | 14.8% | 16.6% | 15.5% | 15.6% | 15.3% | 16.9% | 16.3% | 15.3% |
| Adj Diluted EPS | $2.04 | $2.30 | $2.22 | $2.15 | $2.04 | $2.35 | $2.30 | $2.23 | $2.21 | $2.62 | $2.60 | $2.42 |
| Adj EPS YoY | — | — | — | — | 0.0% | +2.2% | +3.6% | +3.7% | +8.3% | +11.5% | +13.0% | +8.5% |
Organic revenue growth accelerated from ~3% at the start of
2025 to 5-7% by H2 2025. Q1 2025 was soft at 2.5% (weather/calendar day impact), but
rebounded strongly to 5.2%, 6.8%, and 6.4% in subsequent quarters. Full-year organic growth
of 5.3% materially exceeded the ~3% guide at the start of the year. Adj EPS growth peaked at
+13.0% in Q3 2025 before decelerating
to +8.5% in Q4 due to Project Nova investment ramp and Corewell/Fresenius startup costs.
Q4 2025 saw deceleration in both margins and EPS growth.
Adj op margin fell to
15.3% from
16.3% in Q3, and Adj EPS growth
decelerated 450 bps sequentially -- driven by Project Nova investment ramp and Corewell/Fresenius
startup costs. Revenue per requisition was essentially flat (-0.1%) as LifeLabs and new
partnerships mix down the average.
Free Cash Flow Breakdown ($M, Annual)
FCF inflected sharply to $1,359M (+49.5% YoY) after bottoming
at $864M in 2023. CFO of
$1,886M benefited from one-time items
(~$150M from CARES Act tax credit and working capital timing). CapEx rose to
$527M (+24% YoY) as DGX invests in
Project Nova and new lab construction. 2026 CFO is guided at ~$1.75B, implying ~$1.2B normalized
FCF with higher capex.
Acceleration / Deceleration Analysis
Revenue Growth Acceleration:
- FY2023 to FY2024: -6.4% to +6.7% = +1,310 bps acceleration
- FY2024 to FY2025: +6.7% to +11.8% = +510 bps acceleration
- Two consecutive years of acceleration, though 2025 is M&A-driven
Organic Revenue Growth Trajectory (Quarterly):
- 24Q3: 4.2% -> 24Q4: 5.0% -> 25Q1: 2.5% -> 25Q2: 5.2% -> 25Q3: 6.8% -> 25Q4: 6.4%
- +230 bps organic acceleration H1 to H2 2025
Adj EPS Growth Acceleration:
- FY2023 to FY2024: -12.5% to +2.5% = +1,500 bps
- FY2024 to FY2025: +2.5% to +10.3% = +780 bps
- Q4 EPS growth decelerated to +8.5% from +13.0% in Q3 = -450 bps
Share Count: Stable at ~113M diluted shares from 2023-2025; significant prior buyback (136M in 2020 to 113M by 2023). No incremental capital return benefit.
Penalty / Modifier Assessment
| Factor | Impact | Detail |
|---|---|---|
| COVID revenue normalization | -0.50 | 2020-2022 trends distorted by COVID testing; base recovery only clear from 2023 |
| M&A-driven vs organic headline growth | -0.50 | ~60% of 2025 revenue growth was inorganic; headline overstates core momentum |
| Q4 margin/EPS deceleration | -0.25 | Q4 adj EPS growth decelerated to +8.5% from +13.0% in Q3; Nova/Corewell costs |
| PAMA pricing overhang | -0.25 | $100M potential headwind if PAMA reform fails; delayed to 2026 |
| LifeLabs margin dilution | -0.25 | Currently below corp-average margins; integration takes 2-3 years to reach parity |
| Organic growth acceleration to 5.3% | +0.50 | From ~3% to 5.3% FY, with Q3 hitting 6.8% -- well above lab industry norms |
| Advanced diagnostics growth | +0.50 | AD-Detect, autoimmune, cardiometabolic all double-digit; brain health volumes 2x in Q3 |
| Consumer channel momentum | +0.25 | ~$250M revenue growing 20%+; QuestHealth.com + WHOOP, Oura, Function Health |
| Invigorate execution | +0.25 | Consistently hitting 3% annual productivity/savings target; AI deployment progressing |
| Volume inflection | +0.25 | Requisitions +12.4%; organic volume positive at 2-8% across quarters |
Net modifier impact: 0 pts (-1.75 penalties offset by +1.75
positives). The organic growth acceleration and advanced diagnostics momentum are
genuinely encouraging. But the M&A-heavy headline, persistent margin compression from the
COVID peak, Q4 deceleration, and PAMA overhang temper the signal. The base score of 7.0
holds at 7.0 after modifiers.
Transcript Context
Organic growth drivers: Health plan access expansion (Elevance, Sentara) added
>1M new lives effective Jan 2025. Advanced diagnostics (5 key clinical areas) driving test-per-req
and mix improvement. Consumer-initiated testing nearly $250M in 2025.
Invigorate: 3% annual savings target consistently met. Front-end automation
deployed at multiple sites. Employee retention improving toward pre-pandemic levels.
M&A Integration: LifeLabs tracking at or ahead of plan. Corewell Health CoLab
(~$1B revenue in 2026) and Fresenius dialysis testing are significant new relationships.
Advanced Diagnostics: AD-Detect Alzheimer blood tests more than doubled in Q3 2025.
Haystack MRD received FDA breakthrough device designation. Analyzer autoimmune solution seeing
strong primary care adoption.
2026 Guidance: Revenue $11.7-11.82B (+6-7.1%), Adj EPS $10.50-10.70 (+6.6-8.6%),
operating margin expansion expected. Corewell CoLab adds ~$250M organic revenue at low single-digit
margins. Project Nova ramp adds ~$0.25 EPS dilution.
Risks: PAMA reform still unresolved ($100M potential hit). One Big Beautiful Bill
minimal volume impact (30 bps in 2026). Tariffs manageable (<1% China exposure, 80% US-sourced).
Wage inflation persists at 3-4%.
Score Rationale
Score of 7/10 reflects a solid, improving financial trend profile with meaningful positive momentum but several tempering factors.
Bull case (what pushes toward 8+):
- Organic revenue growth inflected from ~3% to 5-7%, well above the 1-2% lab industry norm
- Advanced diagnostics, consumer health, and enterprise partnerships are durable growth vectors
- EPS grew 10%+ in 2025 after years of post-COVID compression
- Margins are expanding again, and FCF is recovering strongly
- 2026 guidance implies continued EPS acceleration
What holds it at 7:
- Headline +11.8% revenue growth is heavily M&A-driven; organic is solid but not exceptional
- Multi-year margin compression from COVID peak (23.8% adj op margin to 15.9%)
- Q4 2025 saw deceleration in both margins and EPS growth
- PAMA remains a structural pricing overhang
- LifeLabs and Corewell are margin-dilutive near-term
- Rev/req essentially flat (+0.1%) as new partnerships mix down the average
- Share count plateaued -- no incremental capital return benefit
Data sourced from Daloopa (company_id: 542) and Quest Diagnostics earnings releases (FY2020 through Q4 2025). All financials in USD. Fiscal year ends December.